fashion -WSS

fashion

author：explore 2025-09-28 23:49:16 - browse：11

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Research misconduct: Proposed new rules face resistance

WSS

EU regulator recommends expanding Mounjaro approval to obesity

Francis Collins on trust in science and how Covid communications failed

Erich Jarvis studies song birds to learn about human stuttering

Texas board proposes rules on abortion law emergency exemption

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Adam's Take: Intra

entertainment

fashion

entertainment

In age of alternative facts, a scholarly course on calling out crap

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

ChatGPT in medicine: STAT answers readers' burning questions

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. officials, researchers try to ease path for bespoke genetic treatments

Medical leaders decry Supreme Court decision on affirmative action

New brain studies show LSD's effects on the brain in full color

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Humana cuts profit projections as Medicare Advantage costs soar

explore

Texas board proposes rules on abortion law emergency exemption

Readout Newsletter: Illumina, CRISPR, Regeneron

Pfizer, Moderna say biotech, pharma drug development is a sprint

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Biotech venture capitalists face new demands from investors

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

hotspot

focus

explore

leisure time